Dr. Reddy’s to expand access to Hepatitis C drug

HYDERABAD, India — Dr. Reddy’s Labs has entered into an agreement with Hetero, under which it will be licensed to distribute and market sofosbuvir tablets in 400-mg dosage strength. The drug is used to treat chronic hepatitis C (under the brand name Resof) in India.

 

Nearly 12 million Indians suffer from chronic hepatitis C, the company said, citing data from the World Health Organization. The disease can affect the liver, potentially causing serious complications. 

 

“Clinical studies have indicated that sofosbuvir 400 mg in combination with other agents achieved very high cure rates, while shortening the duration of treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype,” the company said in a statement.